title: The effects of levodopa and deep brain stimulation on subthalamic local field low-frequency oscillations in Parkinson's disease.
abstract: New adaptive systems for deep brain stimulation (DBS) could in the near future optimize stimulation settings online so as to achieve better control over the clinical fluctuations in Parkinson's disease (PD). Local field potentials (LFPs) recorded from the subthalamic nucleus (STN) in PD patients show that levodopa and DBS modulate STN oscillations. Because previous research has shown that levodopa and DBS variably influence beta LFP activity (8-20 Hz), we designed this study to find out how they affect low-frequency (LF) oscillations (2-7 Hz). STN LFPs were recorded in 19 patients with PD during DBS, after levodopa medication, and during DBS and levodopa intake combined. We investigated the relationship between LF modulations, DBS duration and levodopa intake. We also studied whether LF power depended on disease severity, the patient's clinical condition and whether LF modulations were related to electrode impedances. LF power increased during DBS, after levodopa intake and under both experimental conditions combined. The LF power increase correlated with the levodopa-induced clinical improvement and the higher the electrode impedance, the greater was the LF power change. These data suggest that the LF band could be useful as a control neurosignal for developing novel adaptive DBS systems for patients with PD.
authors.affiliation: Centro Clinico per la Neurostimolazione, le Neurotecnologie ed i Disordini del Movimento, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
authors.forename: Gaia
authors.initials: G
authors.lastname: Giannicola
authors.forename: Manuela
authors.initials: M
authors.lastname: Rosa
authors.forename: Sara
authors.initials: S
authors.lastname: Marceglia
authors.forename: Emma
authors.initials: E
authors.lastname: Scelzo
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Rossi
authors.forename: Domenico
authors.initials: D
authors.lastname: Servello
authors.forename: Claudia
authors.initials: C
authors.lastname: Menghetti
authors.forename: Claudio
authors.initials: C
authors.lastname: Pacchetti
authors.forename: Roberta
authors.initials: R
authors.lastname: Zangaglia
authors.forename: Marco
authors.initials: M
authors.lastname: Locatelli
authors.forename: Elena
authors.initials: E
authors.lastname: Caputo
authors.forename: Filippo
authors.initials: F
authors.lastname: Cogiamanian
authors.forename: Gianluca
authors.initials: G
authors.lastname: Ardolino
authors.forename: Sergio
authors.initials: S
authors.lastname: Barbieri
authors.forename: Alberto
authors.initials: A
authors.lastname: Priori
mesh_terms: D000328:Adult; D000368:Aged; D001683:Biological Clocks / Q000187:drug effects / Q000502:physiology*; D003131:Combined Modality Therapy; D046690:Deep Brain Stimulation / Q000379:methods*; D004567:Electrodes, Implanted; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D020531:Subthalamic Nucleus / Q000187:drug effects / Q000502:physiology* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D007980:Levodopa